---

Medical Treatments: Access

Answer

The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.

The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.

Appraisal number	Year of publication	Technology/condition	Recommendation
TA268	2012	Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma	Recommended in line with marketing authorisation and following agreement of patient access scheme.
TA269	2012	Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	Recommended in line with marketing authorisation and following agreement of patient access scheme.
TA319	2014	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma	Recommended in line with marketing authorisation and following agreement of patient access scheme.
TA321	2014	Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma	Recommended in line with marketing authorisation and following agreement of patient access scheme.
TA3571	2015	Pembrolizumab for advanced melanoma after disease progression with ipilimumab	Recommended in line with marketing authorisation and following agreement of patient access scheme.
TA3661	2015	Pembrolizumab for advanced melanoma not previously treated with ipilimumab	Recommended in line with marketing authorisation and following agreement of patient access scheme.
TA384	2016	Nivolumab for advanced (unresectable or metastatic) melanoma	Recommended in line with marketing authorisation.
TA396	2016	Trametinib in combination with dabrafenib for unresectable or metastatic melanoma	Recommended in line with marketing authorisation.
TA400	2016	Nivolumab in combination with ipilimumab for advanced melanoma	Recommended in line with marketing authorisation and following agreement of patient access scheme.
TA410	2016	Talimogene laherparepvec for unresectable metastatic melanoma	Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.
TA414	2016	Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma	At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.

¹ pembrolizumab within its licensed indication was appraised across two separate appraisals.

NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.

Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.

The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:

https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf

Secondary information

Type

Written question

Reference

57299

Session

2016-17

Grouped for answer

Yes

Subjects

Access Medical treatments Skin cancer

Contains statistics

Yes

Link

View this Written question on www.parliament.uk